...
首页> 外文期刊>Antiviral Research >Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir
【24h】

Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir

机译:通过抗腺病毒siRNA的三重组合增强抑制腺病毒复制,可溶性腺病毒受体捕获瘢痕 - Fc和Cidofovir

获取原文
获取原文并翻译 | 示例

摘要

Adenoviruses (Ad) generally induce mild self-limiting respiratory or intestinal infections but can also cause serious disease with fatal outcomes in immunosuppressed patients. Antiviral drug therapy is an important treatment for adenoviral infections but its efficiency is limited. Recently, we have shown that gene silencing by RNA interference (RNAi) is a promising new approach to inhibit adenoviral infection. In the present in vitro study, we examined whether the efficiency of an RNAi-based anti-adenoviral therapy can be further increased by combination with a virus receptor trap sCAR-Fc and with the antiviral drug cidofovir. Initially, three siRNAs, siE1A_4, siIVa2_2 and Pol-si2, targeting the adenoviral E1A, IVa2 and DNA polymerase mRNAs, respectively, were used for gene silencing. Replication of the Ad was inhibited in a dose dependent manner by each siRNA, but the efficiency of inhibition differed (Pol-si2 > siIVa2_2 > siE1A_4). Double or triple combinations of the siRNAs compared with single siRNAs did not result in a measurably higher suppression of Ad replication. Combination of the siRNAs (alone or mixes of two or three siRNAs) with sCAR-Fc markedly increased the suppression of adenoviral replication compared to the same siRNA treatment without sCAR-Fc. Moreover, the triple combination of a mix of all three siRNAs, sCAR-Fc and cidofovir was about 23-fold more efficient than the combination of siRNAs mix/sCAR-Fc and about 95-fold more efficient than the siRNA mix alone. These data demonstrate that co-treatment of cells with sCAR-Fc and cidofovir is suitable to increase the efficiency of anti-adenoviral siRNAs. (C) 2015 Elsevier B.V. All rights reserved.
机译:腺病毒(AD)通常诱导温和的自限呼吸道或肠道感染,但也可能导致免疫抑制患者的致命结果引起严重的疾病。抗病毒药物治疗是对腺病毒感染的重要治疗,但其效率有限。最近,我们已经表明RNA干扰(RNAi)的基因沉默是一种有希望的新方法来抑制腺病毒感染。在本发明的体外研究中,我们检查了基于RNAI的抗腺病毒治疗的效率是否可以通过与病毒受体捕获疤痕-CC和抗病毒药物Cidofovir组合进一步增加。最初,分别用于分别靶向腺病毒E1a,IVA2和DNA聚合酶MRNA的三个siRNA,Sie1a_4,Siiva2_2和Pol-Si2用于基因沉默。通过每个siRNA以剂量依赖性方式抑制AD的复制,但抑制效率不同(POL-Si2> Siiva2_2> Sie1a_4)。与单个siRNA相比,siRNA的双或三重组合并未导致可测量地抑制AD复制。与瘢痕-FC的siRNA(单独或两种siRNA的混合物)的组合显着增加了与没有瘢痕-Fc的相同siRNA治疗相比的抑制腺病毒复制。此外,除SiRNA混合物/瘢痕-FC的组合比SiRNA混合单独效率比siRNA混合物比siRNA混合物更有效,所有三个siRNA,Surn-Fc和Cidofovir的混合物的三倍组合约为23倍。这些数据表明,具有瘢痕-Fc和Cidofovir的细胞的共处理适合提高抗腺病毒siRNA的效率。 (c)2015 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号